BetterLife Pharma Inc. (BETR.CN)
CAD 0.1
(-5.56%)
CAD 0.1
(-5.56%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 207.85 Thousand CAD | -82.37% |
| 2022 | 1.17 Million CAD | -3.54% |
| 2021 | 1.22 Million CAD | 253.98% |
| 2020 | 345.27 Thousand CAD | -82.91% |
| 2019 | 2.02 Million CAD | -40.97% |
| 2018 | 3.42 Million CAD | 1930.07% |
| 2017 | 168.6 Thousand CAD | -20.87% |
| 2016 | 213.06 Thousand CAD | 312.78% |
| 2015 | -100.13 Thousand CAD | -9284.63% |
| 2014 | -1067.00 CAD | -100.31% |
| 2013 | 341.11 Thousand CAD | 55.76% |
| 2012 | 218.99 Thousand CAD | 124.03% |
| 2011 | 97.75 Thousand CAD | 2352.89% |
| 2010 | -4339.00 CAD | 77.14% |
| 2009 | -18.97 Thousand CAD | 36.15% |
| 2008 | -29.72 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.81 Million CAD | 141.39% |
| 2024 Q1 | 753.04 Thousand CAD | 262.3% |
| 2023 Q4 | 207.85 Thousand CAD | -61.35% |
| 2023 FY | 207.85 Thousand CAD | -82.37% |
| 2023 Q1 | 846.43 Thousand CAD | -28.2% |
| 2023 Q2 | 1.11 Million CAD | 31.31% |
| 2023 Q3 | 537.77 Thousand CAD | -51.61% |
| 2022 Q2 | 1.61 Million CAD | 13.25% |
| 2022 Q1 | 1.42 Million CAD | 16.42% |
| 2022 Q4 | 1.17 Million CAD | -4.33% |
| 2022 Q3 | 1.23 Million CAD | -23.54% |
| 2022 FY | 1.17 Million CAD | -3.54% |
| 2021 Q2 | -3.72 Million CAD | -879.07% |
| 2021 Q3 | -1.75 Million CAD | 52.88% |
| 2021 Q4 | 1.22 Million CAD | 169.69% |
| 2021 FY | 1.22 Million CAD | 253.98% |
| 2021 Q1 | 477.78 Thousand CAD | 38.38% |
| 2020 Q2 | 2.02 Million CAD | -5.66% |
| 2020 FY | 345.27 Thousand CAD | -82.91% |
| 2020 Q4 | 345.27 Thousand CAD | -90.29% |
| 2020 Q1 | 2.14 Million CAD | 6.07% |
| 2020 Q3 | 3.55 Million CAD | 75.88% |
| 2019 Q2 | -6.33 Million CAD | -258.59% |
| 2019 FY | 2.02 Million CAD | -40.97% |
| 2019 Q4 | 2.02 Million CAD | 141.7% |
| 2019 Q3 | -4.84 Million CAD | 23.58% |
| 2019 Q1 | 3.99 Million CAD | 16.79% |
| 2018 FY | 3.42 Million CAD | 1930.07% |
| 2018 Q4 | 3.42 Million CAD | 12.68% |
| 2018 Q2 | 4.82 Million CAD | 43.33% |
| 2018 Q1 | 3.36 Million CAD | 1896.55% |
| 2018 Q3 | 3.03 Million CAD | -37.04% |
| 2017 Q2 | 478.72 Thousand CAD | 9.88% |
| 2017 FY | 168.6 Thousand CAD | -20.87% |
| 2017 Q4 | 168.6 Thousand CAD | 372.73% |
| 2017 Q3 | -61.82 Thousand CAD | -112.91% |
| 2017 Q1 | 435.68 Thousand CAD | 104.48% |
| 2016 Q3 | -85.84 Thousand CAD | -2054.72% |
| 2016 Q2 | -3983.91 CAD | 89.22% |
| 2016 FY | 213.06 Thousand CAD | 312.78% |
| 2016 Q4 | 213.06 Thousand CAD | 348.21% |
| 2016 Q1 | -36.95 Thousand CAD | 63.1% |
| 2015 Q1 | -33.78 Thousand CAD | -3066.26% |
| 2015 FY | -100.13 Thousand CAD | -9284.63% |
| 2015 Q4 | -100.13 Thousand CAD | 46.7% |
| 2015 Q3 | -187.88 Thousand CAD | 30.49% |
| 2015 Q2 | -270.28 Thousand CAD | -700.03% |
| 2014 FY | -1067.00 CAD | -100.31% |
| 2014 Q4 | -1067.00 CAD | -100.27% |
| 2014 Q3 | 391.56 Thousand CAD | 9.17% |
| 2014 Q2 | 358.66 Thousand CAD | 1.08% |
| 2014 Q1 | 354.84 Thousand CAD | 4.03% |
| 2013 Q3 | 233.81 Thousand CAD | 3.58% |
| 2013 Q1 | 206.35 Thousand CAD | -5.77% |
| 2013 Q2 | 225.74 Thousand CAD | 9.39% |
| 2013 FY | 341.11 Thousand CAD | 55.76% |
| 2013 Q4 | 341.11 Thousand CAD | 45.89% |
| 2012 Q2 | 160.51 Thousand CAD | 18.01% |
| 2012 FY | 218.99 Thousand CAD | 124.03% |
| 2012 Q4 | 218.99 Thousand CAD | 662.9% |
| 2012 Q3 | 28.7 Thousand CAD | -82.12% |
| 2012 Q1 | 136.01 Thousand CAD | 39.15% |
| 2011 Q4 | 97.75 Thousand CAD | 13.56% |
| 2011 Q3 | 86.08 Thousand CAD | -23.97% |
| 2011 Q2 | 113.22 Thousand CAD | -15.72% |
| 2011 Q1 | 134.33 Thousand CAD | 3196.04% |
| 2011 FY | 97.75 Thousand CAD | 2352.89% |
| 2010 FY | -4339.00 CAD | 77.14% |
| 2010 Q2 | -2744.00 CAD | 55.73% |
| 2010 Q3 | -1900.00 CAD | 30.76% |
| 2010 Q4 | -4339.00 CAD | -128.37% |
| 2010 Q1 | -6198.00 CAD | 67.34% |
| 2009 FY | -18.97 Thousand CAD | 36.15% |
| 2009 Q4 | -18.97 Thousand CAD | 0.0% |
| 2008 FY | -29.72 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -125.08 Thousand CAD | 266.167% |
| Asep Medical Holdings Inc | -44.72 Thousand CAD | 564.77% |
| BioVaxys Technology Corp. | -977.00 CAD | 21374.309% |
| ChitogenX Inc. | 3.84 Million CAD | 94.587% |
| Rapid Dose Therapeutics Corp. | 2.29 Million CAD | 90.934% |
| Defence Therapeutics Inc. | 1.68 Million CAD | 87.7% |
| Entheon Biomedical Corp. | -344.63 Thousand CAD | 160.311% |
| Gemina Laboratories Ltd. | 284.33 Thousand CAD | 26.9% |
| Glow Lifetech Corp. | 116.15 Thousand CAD | -78.95% |
| Lexston Life Sciences Corp. | -390.4 Thousand CAD | 153.24% |
| Pharmala Biotech Holdings Inc. | 58.49 Thousand CAD | -255.33% |
| Doseology Sciences Inc. | -1.06 Million CAD | 119.604% |
| MYND Life Sciences Inc. | 2.99 Million CAD | 93.071% |
| Nova Mentis Life Science Corp. | -8088.00 CAD | 2669.857% |
| PharmaTher Holdings Ltd. | -2.13 Million CAD | 109.743% |
| PreveCeutical Medical Inc. | 3.83 Million CAD | 94.577% |
| Telescope Innovations Corp. | -719.49 Thousand CAD | 128.888% |